OpenEvidence Inc.
Headquarters
Miami, FLFounded
2022CEO / Founder
Daniel NadlerEmployees
51-200Funding
Series D+ — $700MProducts
1 product listedAvg. AI Score
8.3/10Website
www.openevidence.com
Profile updated
About OpenEvidence Inc.
OpenEvidence Inc. is an American artificial intelligence company that develops a medical search engine for clinical decision support. Verified physicians use the platform at no cost to query peer-reviewed medical literature and receive synthesized, cited answers to clinical questions. The company was founded in 2022 by Daniel Nadler, who previously founded the financial analytics firm Kensho Technologies (acquired by S&P Global in 2018), and Zachary Ziegler, a Harvard machine learning researcher who serves as chief technology officer. OpenEvidence is headquartered in Miami, Florida.
The core product is free to verified U.S. physicians, with revenue generated through advertising. Its DeepConsult feature, launched in July 2025, runs deeper multi-step research across the medical literature. OpenEvidence holds content partnerships with the New England Journal of Medicine and JAMA Network publications and works with organizations including the American Medical Association, the National Comprehensive Cancer Network, and the American Academy of Family Physicians. The company came up through the Mayo Clinic Platform Accelerate program, and its AI engine also powers Elsevier's ClinicalKey AI. As of December 2025 the platform counted roughly 760,000 registered U.S. physicians and about 18 million clinical consultations per month.
OpenEvidence has raised approximately $700 million. Sequoia Capital led a $75 million Series A in February 2025 at a $1 billion valuation, followed by a $210 million round led by GV and Kleiner Perkins in July 2025 at $3.5 billion, a $200 million Series C in October 2025 at $6 billion, and a $250 million Series D led by Thrive Capital and DST Global in January 2026 that valued the company at $12 billion. Other backers include Nvidia, Blackstone, Craft Ventures, and Mayo Clinic. The company ranked No. 32 on the 2026 CNBC Disruptor 50 list and operates with a small staff, with third-party estimates ranging from roughly 60 to 120 employees.
Specialties
Financials
Dated, source-cited figures. Estimates are marked.
Products by OpenEvidence Inc.
All products by OpenEvidence Inc. reviewed by our AI panel of experts.
How Our Review Panel Scores OpenEvidence Inc.
Six independent reviewer personalities assessed OpenEvidence Inc.'s product on their own terms. They landed within 0.9 points of each other, an unusually strong consensus.
Averaged across 1 reviewed product in our catalog. Scores are out of 10.
Competitive Landscape
Who OpenEvidence Inc. competes with, and how they differ.
Long-established point-of-care clinical reference tool used by physicians for evidence-based answers, but relies on human-curated editorial summaries rather than an AI-generated search interface over primary literature.
Focuses on ambient clinical documentation and note generation from patient encounters rather than answering clinical questions from medical literature.
9 products reviewed on TopReviewed
Targets clinical documentation automation from patient-physician conversations, not literature search or evidence synthesis for clinical decision-making.
1 product reviewed on TopReviewed
AI voice assistant for clinical documentation and EHR workflows, competing on physician time savings rather than evidence retrieval or clinical question answering.
1 product reviewed on TopReviewed
Ambient AI scribe for capturing and structuring clinical visit notes, a documentation tool rather than a literature-based answer engine.
1 product reviewed on TopReviewedPhysician-focused professional network and communication platform that also offers some clinical reference tools, competing more on physician engagement and workflow than on cited evidence-based Q&A.
Company Timeline
Key milestones in OpenEvidence Inc.'s history, with sources.
- Funding
Series D — $250M co-led by Thrive Capital and DST Global at $12B valuation
OpenEvidence raised $250 million in a Series D round that doubled its valuation to $12 billion, its fourth raise in under a year, bringing total funding to nearly $700 million.
cnbc.com - Funding
Series C — $200M led by Google Ventures at $6B valuation
OpenEvidence raised $200 million in a Series C round three months after its Series B, valuing the company at $6 billion; Sequoia, Kleiner Perkins, Thrive and Coatue followed on, joined by new investors BOND, Blackstone and Craft.
digitalhealthnews.com - Milestone
OpenEvidence AI becomes first AI in history to score a perfect 100% on the USMLE
OpenEvidence's AI system scored 325/325 on a standardized USMLE benchmark across Steps 1, 2 CK and 3, the first perfect score by any AI on the exam.
prnewswire.com - Funding
Series B — $210M co-led by Google Ventures and Kleiner Perkins at $3.5B valuation
OpenEvidence raised $210 million at a $3.5 billion valuation, with Sequoia Capital following on and Coatue, Conviction and Thrive also participating, taking total funding since founding above $300 million.
prnewswire.com - Partnership
Strategic content agreement with the JAMA Network
OpenEvidence signed a multi-year content agreement with the American Medical Association's JAMA Network, making full-text articles from JAMA, JAMA Network Open and 11 specialty journals available within the platform.
prnewswire.com - Funding
Series A — $75M led by Sequoia Capital at $1B valuation
OpenEvidence closed its first institutional round, $75 million led by Sequoia Capital at a $1 billion valuation, alongside a new content partnership with the New England Journal of Medicine.
cnbc.com - Milestone
OpenEvidence AI becomes first AI to score above 90% on the USMLE
OpenEvidence's AI model scored above 90% on the United States Medical Licensing Examination, the first AI to clear that mark, following its participation in the Mayo Clinic Platform Accelerate program earlier that year.
prnewswire.com - Founded
OpenEvidence founded by Daniel Nadler and Zachary Ziegler
OpenEvidence was founded in Miami by Daniel Nadler (previously founder of Kensho Technologies, acquired by S&P Global in 2018) and Harvard machine-learning researcher Zachary Ziegler to build an AI-powered medical search engine for clinicians.
en.wikipedia.org
Explore AI Software Reviews
Browse multi-perspective AI panel reviews across hundreds of AI tools, agents, and platforms. Find the right software with insights from CTO, Developer, Marketer, Finance, and User perspectives.